Sponsors (4)
The measure directs research funding, VA precision-oncology support, and education to improve prostate cancer outcomes, but increases the likelihood of PSA overtesting/overdiagnosis and raises taxpayer expectations that entail federal budget trade-offs.
Men with prostate cancer (especially older men) gain from increased NIH/NCI research funding and FY2025 appropriations that could improve prevention, detection, and treatment.
Patients and healthcare providers will receive education that promotes earlier detection conversations, likely increasing diagnoses at localized stages where survival is very high.
Veterans with prostate cancer may get improved access to precision oncology services through the VA's 21 Centers of Excellence.
Men receiving more screening may face increased PSA testing that raises the risk of overdiagnosis and overtreatment of indolent tumors.
Highlighting large appropriations can raise public expectations for new services, creating budget trade-offs and potential costs for taxpayers.
Based on analysis of 2 sections of legislative text.
Makes nonbinding findings about prostate cancer prevalence, risk factors, screening, research funding, and stresses patient-provider education about screening.
Official title: Expressing support for the designation of September 2025 as "National Prostate Cancer Awareness Month".
Introduced October 6, 2025 by Michael Dean Crapo · Last progress October 6, 2025
Declares congressional findings about prostate cancer: its prevalence, risk factors (age, race, family history), screening considerations, survival rates, and ongoing research efforts. Notes recent federal research funding levels for NIH and NCI, Department of Defense prostate cancer research support, and VA Precision Oncology Centers, and emphasizes educating patients and health care providers so men can discuss screening with their physicians. The measure is a nonbinding statement stressing the importance of awareness, shared decision-making about screening, and continued research into prevention, detection, and treatment. It does not change funding or create new programs but highlights existing federal investments and clinical resources.